Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 1, 2013, Pages 94-100

  Lee, Chun Ming ^a,b,c   Lai, Chih Cheng ^d   Wang, Ying Yue ^b   Lee, Meng Chih ^a,e   Hsueh, Po Ren ^f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e Taichung Hospital   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; Ertapenem; Extended spectrum lactamase; Hospital ecology; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG USE; DRUG UTILIZATION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TAIWAN; TREND STUDY;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DRUG UTILIZATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84870748768     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.09.018     Document Type: Article

References (24)

1. Asche C., McAdam-Marx C., Seal B., Crookston B., Mullins C.D. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother 2008, 61:1162-1168.
2. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 18th informational supplement (M100-S19) 2009, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk susceptibility tests; approved standard - ninth edition, M2-A9 2006, CLSI, Wayne, PA.
4. Cook P.P., Catrou P.G., Christie J.D., Young P.D., Polk R.E. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004, 53:853-859.
5. Eagye K.J., Nicolau D.P. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010, 31:485-490.
6. Eagye K.J., Nicolau D.P. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 year in not associated with the use of ertapenem. J Antimicrob Chemother 2011, 66:1392-1395.
7. Georges B., Conil J.M., Dubouix A., Archambaud M., Bonnet E., Saivin S., et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006, 34:1636-1641.
8. Goff D.A., Mangino J.E. Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem. J Infect 2008, 57:123-127.
9. Goldstein E.J., Citron D.M., Peraino V., Elgourt T., Meibohm A.R., Lu S. Introduction of ertapenem into a hospital formulary: effect of antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:5122-5126.
10. Hsueh P.R., Chen W.H., Teng L.J., Luh K.T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005, 26:43-49.
11. Hsueh P.R., Chen W.H., Luh K.T. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infection from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005, 26:463-472.
12. Kaye K.S., Kanafani Z.A., Dodds A.E., Engemann J.J., Weber S.G., Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:2192-2196.
13. Lai C.C., Wang C.Y., Chu C.C., Tan C.K., Lu C.L., Lee Y.L., et al. Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital from 2000 to 2009. Eur J Clin Microbiol Infect Dis 2011, 30:265-267.
14. Lai C.C., Wang C.Y., Chu C.C., Tan C.K., Lu C.L., Lee Y.C., et al. Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university in Taiwan from 2000 to 2009. J Antimicrob Chemother 2011, 66:1374-1382.
15. Lee Y.J., Liu H.Y., Lin Y.C., Sun K.L., Chun C.L., Hsueh P.R. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but no ciprofloxacin use. Int J Antimicrob Agents 2010, 35:261-264.
16. Lima A.L., Oliveira P.R., Paula A.P., Dal-Paz K., Rossi F., Zumiotti A.V. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009, 30:487-490.
17. Lima A.L., Oliveira P.R., Paula A.P., Dal-Paz K., Almeida J.N., Félix Cda S., et al. Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis 2011, 15:1-5.
18. Metz-Gercek S., Maieron A., Strauss R., Wieninger P., Apfalter P., Mittermayer H. Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009, 9:61.
19. Meyer E., Schwab F., Gastmeier P., Rueden H., Daschner F.D. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006, 34:303-309.
20. Mutnick A.H., Rhomberg P.R., Sader H.S., Jones R.N. Antimicrobial usage and resistance trend relationship from MYSTIC programme in North America. J Antimicrob Chemother 2004, 53:290-296.
21. National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: 13th informational supplement. M100-S13 (M7) 2003, NCCLS, Wayne, PA.
22. Nguyen L.H., Hsu D.I., Ganapathy V., Shriner K., Wong-Beringer A. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. J Antimicrob Chemother 2008, 61:714-720.
23. Pakyz A.L., Oinonen M., Polk R.E. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:1983-1986.
24. Tam V.H., Gamez E.A., Weston J.S., Gerard L.N., Larocco M.T., Caeiro J.P., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008, 46:862-867.